P04.13
Newborn affected by maternal use of anticonvulsants
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 Code P04.13 refers to newborns who are affected by the use of anticonvulsant medications taken by their mothers during pregnancy. Anticonvulsants are drugs commonly used to control seizures, especially in women with epilepsy. While these medications are often essential for the mother's health, they can sometimes influence the developing fetus, leading to various health concerns at birth.
Causes & Symptoms
Clinical Causes: Maternal use of anticonvulsant medications during pregnancy Certain types of anticonvulsants crossing the placental barrier and affecting fetal development High doses or specific types of anticonvulsants with known teratogenic effects
Key Symptoms: Hypoglycemia (low blood sugar levels at birth) Respiratory difficulties or breathing problems Hypotonia (reduced muscle tone or floppy baby) Congenital anomalies such as cleft lip or palate Neonatal jaundice (yellowing of the skin and eyes) Feeding difficulties
Diagnostic & Treatment
Diagnosis Path: Diagnosing newborns affected by maternal anticonvulsant use involves a combination of maternal medical history, particularly medication intake during pregnancy, and clinical assessments of the newborn's health. Physical examinations may reveal congenital abnormalities or signs of toxicity. Additional laboratory tests might include blood sugar measurements, liver function tests, and imaging studies if structural anomalies are suspected. Identifying these cases early can help healthcare providers coordinate appropriate care and support.
Treatment Protocols: Management of infants affected by maternal anticonvulsant use typically focuses on supportive and symptomatic care. This may involve:
Clinical Advice & FAQs
Billing Guidance
Is P04.13 a billable ICD-10 code?
Yes, P04.13 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report P04.13?
Clinical documentation must specify the nature of Newborn affected by maternal use of anticonvulsants and any associated comorbidities for accurate reporting.
Cite this Clinical Reference